Free Newsletter
ALSO NOTED: Sepracor chair to retire in May; Study shows Glaxo drug outpacing Pfizer's Spiriva;
> Sepracor chairman Timothy Barberich will retire by May, according to a disclosure filed with the Securities and Exchange commission; Barberich is the drug maker's former CEO. Report
> A GlaxoSmithKline-funded study showed that chronic obstructive pulmonary disease patients using its asthma drug Seretide (Advair) were half as likely to die as those using Pfizer's Spiriva. Release
> Pfizer India sold several of its brands, including Listerine and Benadryl, to Johnson & Johnson for $55 million. Report
> Cephalon is asking the FDA to extend the use of its chemo drug Treanda to lymphatic cancer in patients who have stopped responding to Genentech's Rituxin. Release
> India-based Wockhardt got U.S. FDA approval to sell its copycat form of Zyrtec, the allergy med. Report
And Finally... Researchers have identified the reasons why fish oil protects people from Alzheimer's disease. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: